Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
US FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer February 17, 2026
Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma February 9, 2026
FDA Accepted NDA for Zanzalintinib – Tecentriq Combo in Patients with Metastatic CRC February 9, 2026
Positive Year-End Interim Clinical Progress from Ph 2 Study of Ampligen – Imfinzi Combo in Pancreatic Cancer Reported February 9, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 9, 2026
Results announced from Ph 3 study of Anbenitamab (KN026) in HER2+ve gastric or gastroesophageal junction cancer (GC/GEJ) February 1, 2026
Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for GIST Patients February 1, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers February 1, 2026
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma from the eNRGy Trial January 18, 2026
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat CRC January 18, 2026
Positive Follow-Up Data from Ph 2 Trial Shows Extended Long-Term OS Benefit with Elraglusib + Chemo for Metastatic Pancreatic Cancer January 18, 2026
Ph 1/2a Data of IMC002 Highlighted a Durable Complete Response Beyond 1 Year and a 66.7% ORR in Advanced GC/GEJ January 18, 2026
